Analysts expect that Qiagen N.V. (NASDAQ:QGEN) will announce $365.10 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Qiagen N.V.’s earnings, with estimates ranging from $364.20 million to $366.00 million. Qiagen N.V. posted sales of $338.70 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 7.8%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 1st.

According to Zacks, analysts expect that Qiagen N.V. will report full year sales of $365.10 million for the current fiscal year, with estimates ranging from $1.40 billion to $1.44 billion. For the next financial year, analysts forecast that the company will post sales of $1.52 billion per share, with estimates ranging from $1.50 billion to $1.54 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Qiagen N.V..

Qiagen N.V. (NASDAQ:QGEN) last announced its earnings results on Thursday, July 27th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The business had revenue of $349 million for the quarter, compared to the consensus estimate of $353.09 million. During the same period last year, the business posted $0.24 EPS. The company’s revenue was up 4.4% on a year-over-year basis.

QGEN has been the subject of several research analyst reports. Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a research report on Monday, May 15th. Barclays PLC reissued a “buy” rating and set a $33.00 price objective on shares of Qiagen N.V. in a research report on Monday, May 15th. DZ Bank AG reissued a “neutral” rating on shares of Qiagen N.V. in a research report on Monday, May 15th. TheStreet raised Qiagen N.V. from a “c” rating to a “b” rating in a research report on Monday, June 5th. Finally, BidaskClub cut Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 10th. Nine equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $33.17.

A number of institutional investors have recently bought and sold shares of QGEN. FNY Managed Accounts LLC acquired a new position in Qiagen N.V. in the 1st quarter valued at approximately $103,000. Acrospire Investment Management LLC raised its holdings in Qiagen N.V. by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after acquiring an additional 349 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new position in Qiagen N.V. in the 1st quarter valued at approximately $114,000. Quadrant Capital Group LLC raised its holdings in Qiagen N.V. by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after acquiring an additional 225 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in Qiagen N.V. in the 1st quarter valued at approximately $207,000. 63.01% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Qiagen N.V. (QGEN) Expected to Announce Quarterly Sales of $365.10 Million” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/09/06/qiagen-n-v-qgen-expected-to-announce-quarterly-sales-of-365-10-million.html.

Qiagen N.V. (NASDAQ QGEN) traded down 0.69% during midday trading on Friday, reaching $31.71. The company’s stock had a trading volume of 1,855,410 shares. Qiagen N.V. has a 52 week low of $24.86 and a 52 week high of $35.26. The stock has a 50 day moving average of $32.43 and a 200 day moving average of $31.54. The firm has a market capitalization of $7.24 billion, a PE ratio of 96.97 and a beta of 1.15.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Get a free copy of the Zacks research report on Qiagen N.V. (QGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Stock Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related stocks with our FREE daily email newsletter.